Vistagen secures patent for non-opioid pain treatment
SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...
Will Donald Trump’s new US sovereign wealth fund take aim at Chinese assets?
Analysts caution the recently authorised fund could compete with Chinese state investment or buy overseas holdings like ...
Guggenheim raises Spotify stock target to $675, retains buy rating
Guggenheim Securities updated its outlook on Spotify Technology SA (NYSE:SPOT), increasing the price target to $675 from the previous $520 while retaining a Buy recommendation on the shares. The ...